Executive cash compensation data for nonfounders revealed a 3% year-over-year rise.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The author declares no competing financial interests.
Rights and permissions
About this article
Cite this article
Rychlik, B. Pay increases still healthy for nonfounder executives at private life sciences companies. Nat Biotechnol 32, 393–395 (2014). https://doi.org/10.1038/nbt.2878
Published:
Issue Date:
DOI: https://doi.org/10.1038/nbt.2878
This article is cited by
-
Compensation inflation remains consistent at private life science companies
Nature Biotechnology (2016)
-
Total target cash compensation shows a healthy increase at private life-science companies
Nature Biotechnology (2015)